- Home
- HSHP vs ADCT Comparison
HSHP vs ADCT Comparison
Compare HSHP & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- ADCT
- Stock Information
- Founded
- HSHP 2021
- ADCT 2011
- Country
- HSHP Bermuda
- ADCT Switzerland
- Employees
- HSHP N/A
- ADCT N/A
- Industry
- HSHP
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- ADCT Health Care
- Exchange
- HSHP Nasdaq
- ADCT Nasdaq
- Market Cap
- HSHP 268.6M
- ADCT 241.0M
- IPO Year
- HSHP 2023
- ADCT 2020
- Fundamental
- Price
- HSHP $6.29
- ADCT $2.97
- Analyst Decision
- HSHP
- ADCT Strong Buy
- Analyst Count
- HSHP 0
- ADCT 6
- Target Price
- HSHP N/A
- ADCT $7.80
- AVG Volume (30 Days)
- HSHP 191.0K
- ADCT 922.1K
- Earning Date
- HSHP 08-20-2025
- ADCT 08-05-2025
- Dividend Yield
- HSHP 6.83%
- ADCT N/A
- EPS Growth
- HSHP 185.76
- ADCT N/A
- EPS
- HSHP 0.28
- ADCT N/A
- Revenue
- HSHP $121,972,000.00
- ADCT $75,817,000.00
- Revenue This Year
- HSHP $11.22
- ADCT $10.65
- Revenue Next Year
- HSHP $25.90
- ADCT $15.05
- P/E Ratio
- HSHP $24.21
- ADCT N/A
- Revenue Growth
- HSHP 107.17
- ADCT 10.49
- 52 Week Low
- HSHP $4.29
- ADCT $1.05
- 52 Week High
- HSHP $8.74
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- HSHP 56.61
- ADCT 53.61
- Support Level
- HSHP $5.76
- ADCT $2.66
- Resistance Level
- HSHP $6.44
- ADCT $2.88
- Average True Range (ATR)
- HSHP 0.17
- ADCT 0.21
- MACD
- HSHP -0.01
- ADCT -0.05
- Stochastic Oscillator
- HSHP 57.22
- ADCT 53.52
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).